These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29599338)

  • 1. TRAP1 Inhibition Increases Glutamine Synthetase Activity in Glutamine Auxotrophic Non-small Cell Lung Cancer Cells.
    Vo VTA; Choi JW; Phan ANH; Hua TNM; Kim MK; Kang BH; Jung SH; Yong SJ; Jeong Y
    Anticancer Res; 2018 Apr; 38(4):2187-2193. PubMed ID: 29599338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
    Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
    J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAP1 regulates autophagy in lung cancer cells.
    Barbosa IA; Vega-Naredo I; Loureiro R; Branco AF; Garcia R; Scott PM; Oliveira PJ
    Eur J Clin Invest; 2018 Apr; 48(4):. PubMed ID: 29383696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic targeting of NRF2 potentiates the efficacy of the TRAP1 inhibitor G-TPP through reduction of ROS detoxification in colorectal cancer.
    Tsai HY; Bronner MP; March JK; Valentine JF; Shroyer NF; Lai LA; Brentnall TA; Pan S; Chen R
    Cancer Lett; 2022 Nov; 549():215915. PubMed ID: 36113636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Necrosis Factor Receptor-associated Protein 1 (TRAP1) Mutation and TRAP1 Inhibitor Gamitrinib-triphenylphosphonium (G-TPP) Induce a Forkhead Box O (FOXO)-dependent Cell Protective Signal from Mitochondria.
    Kim H; Yang J; Kim MJ; Choi S; Chung JR; Kim JM; Yoo YH; Chung J; Koh H
    J Biol Chem; 2016 Jan; 291(4):1841-1853. PubMed ID: 26631731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knock-down of PSAT1 Enhances Sensitivity of NSCLC Cells to Glutamine-limiting Conditions.
    Jin HO; Hong SE; Kim JY; Jang SK; Kim YS; Sim JH; Oh AC; Kim H; Hong YJ; Lee JK; Park IC
    Anticancer Res; 2019 Dec; 39(12):6723-6730. PubMed ID: 31810937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
    Zismanov V; Drucker L; Gottfried M
    Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.
    Agorreta J; Hu J; Liu D; Delia D; Turley H; Ferguson DJ; Iborra F; Pajares MJ; Larrayoz M; Zudaire I; Pio R; Montuenga LM; Harris AL; Gatter K; Pezzella F
    Mol Cancer Res; 2014 May; 12(5):660-9. PubMed ID: 24567527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
    Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
    Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligodendroglioma Cells Lack Glutamine Synthetase and Are Auxotrophic for Glutamine, but Do not Depend on Glutamine Anaplerosis for Growth.
    Chiu M; Taurino G; Bianchi MG; Ottaviani L; Andreoli R; Ciociola T; Lagrasta CAM; Tardito S; Bussolati O
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
    Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
    Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
    Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
    Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
    Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells.
    Palladino G; Notarangelo T; Pannone G; Piscazzi A; Lamacchia O; Sisinni L; Spagnoletti G; Toti P; Santoro A; Storto G; Bufo P; Cignarelli M; Esposito F; Landriscina M
    Endocr Relat Cancer; 2016 Sep; 23(9):699-709. PubMed ID: 27422900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carnosine suppresses human glioma cells under normoxic and hypoxic conditions partly via inhibiting glutamine metabolism.
    Fang YJ; Wu M; Chen HN; Wen TT; Lyu JX; Shen Y
    Acta Pharmacol Sin; 2021 May; 42(5):767-779. PubMed ID: 32782394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
    Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
    J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.